Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I first-in-human, randomized, placebo-controlled, double-blind trial of LP352 four-part trial including single ascending dose (SAD) and MAD assessments in healthy volunteers

Next Previous
Trial Profile

Phase I first-in-human, randomized, placebo-controlled, double-blind trial of LP352 four-part trial including single ascending dose (SAD) and MAD assessments in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bexicaserin (Primary)
  • Indications Developmental disabilities; Epilepsy; Partial epilepsies
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Longboard Pharmaceuticals

Most Recent Events

  • 30 Aug 2023 According to a Longboard Pharmaceuticals media release, data from this trial will be presented at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting.
  • 06 Dec 2022 Results presented at the 76th Annual Meeting of the American Epilepsy Society
  • 26 Apr 2022 Results evaluating the PK, PD, safety and tolerability of single doses of LP352 administered to healthy subjects presented at the 74th Annual Meeting of the American Academy of Neurology 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top